Recent Finacing
Recent Raise
Carisma Therapeutics develops engineered CAR‑macrophage cell therapies that combine antigen recognition and macrophage effector/APC functions for solid tumors; lead anti‑HER2 candidate CT‑0508 is in Phase I trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Carisma Therapeutics.
